CN1448138A - Artesunate and dihydroarteannuin medicine preparation for proofing formation of blood vessel and use thereof - Google Patents
Artesunate and dihydroarteannuin medicine preparation for proofing formation of blood vessel and use thereof Download PDFInfo
- Publication number
- CN1448138A CN1448138A CN 03116762 CN03116762A CN1448138A CN 1448138 A CN1448138 A CN 1448138A CN 03116762 CN03116762 CN 03116762 CN 03116762 A CN03116762 A CN 03116762A CN 1448138 A CN1448138 A CN 1448138A
- Authority
- CN
- China
- Prior art keywords
- artesunate
- dihydroartemisinine
- tumor
- blood vessel
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 title claims description 59
- 229960004991 artesunate Drugs 0.000 title claims description 59
- 239000003814 drug Substances 0.000 title abstract description 51
- 210000004204 blood vessel Anatomy 0.000 title description 11
- 230000015572 biosynthetic process Effects 0.000 title description 2
- 229930187998 Dihydroarteannuin Natural products 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 41
- 239000007924 injection Substances 0.000 claims abstract description 26
- 238000002347 injection Methods 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 238000002512 chemotherapy Methods 0.000 claims abstract description 4
- BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 claims description 40
- 229960002521 artenimol Drugs 0.000 claims description 39
- 239000007788 liquid Substances 0.000 claims description 28
- 239000004005 microsphere Substances 0.000 claims description 27
- 230000033115 angiogenesis Effects 0.000 claims description 26
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 230000002792 vascular Effects 0.000 claims description 12
- 230000007998 vessel formation Effects 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000011226 adjuvant chemotherapy Methods 0.000 claims description 3
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 3
- 229920002988 biodegradable polymer Polymers 0.000 claims description 3
- 239000004621 biodegradable polymer Substances 0.000 claims description 3
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 abstract description 18
- 229960004191 artemisinin Drugs 0.000 abstract description 17
- 229930191701 arteannuin Natural products 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000007246 mechanism Effects 0.000 abstract description 3
- 239000011806 microball Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 31
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 15
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 13
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 11
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 229930101531 artemisinin Natural products 0.000 description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 10
- 210000005239 tubule Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 210000003556 vascular endothelial cell Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 201000004792 malaria Diseases 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 238000013508 migration Methods 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 6
- 239000003430 antimalarial agent Substances 0.000 description 6
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 6
- 238000004043 dyeing Methods 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 5
- 229960000890 hydrocortisone Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 4
- 230000000078 anti-malarial effect Effects 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- BJDCWCLMFKKGEE-HVDUHBCDSA-N dihydroartemisinin group Chemical group C[C@@]12OO[C@]34[C@@H](CC1)[C@@H](CC[C@H]3[C@H](C(O[C@@H]4O2)O)C)C BJDCWCLMFKKGEE-HVDUHBCDSA-N 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 229930016266 dihydroartemisinin Natural products 0.000 description 3
- 210000003725 endotheliocyte Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 210000003606 umbilical vein Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010063094 Cerebral malaria Diseases 0.000 description 2
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- 101150030763 Vegfa gene Proteins 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000512 collagen gel Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000006444 vascular growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- 235000001405 Artemisia annua Nutrition 0.000 description 1
- 240000000011 Artemisia annua Species 0.000 description 1
- QWQSMEDUZQDVLA-ZRAAZYCQSA-N Artemisinin C Natural products O=C1C(=C)[C@H]2[C@@]3(O1)[C@@H]1[C@@](C)(O1)CC[C@H]3[C@H](C)CC2 QWQSMEDUZQDVLA-ZRAAZYCQSA-N 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- -1 Carbonyl Chemical group 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000009701 Embryo Loss Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000827798 Hemerocallis citrina Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 241001299553 Ilex chinensis Species 0.000 description 1
- 241001100935 Ilex purpurea Species 0.000 description 1
- 235000003366 Ilex purpurea Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960000981 artemether Drugs 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 description 1
- 229940026455 cedrol Drugs 0.000 description 1
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001886 cortisols Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960003753 nitric oxide Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229930183339 qinghaosu Natural products 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to medicine preparation of arteannuin and dihydroartemisine for resisting vascularization and its use. The preparation has arteannuin or dihydroartemisine as main component and is prepared into microball injection. It is used in treating tumor vascularization and other vascularization relevant diseases and may be also used in chemotherapy of tumor. Its slow release and absorption in the administrated part results in the acting period of the medicine. The present invention is based on vascularization theory, describes the function and mechanism of single Chinese medicinal component, is one important direction for developing Chinese medicine theory and provides basis for developing the new use of artemisine medicine.
Description
Affiliated technical field
The invention belongs to pharmaceutical preparation, relate to pharmaceutical preparation of arteannuin and derivant thereof and uses thereof.Relate in particular to the pharmaceutical preparation and the medicinal usage aspect blood vessel formation against function thereof of artesunate and dihydroartemisinine.
Background technology
Angiogenesis is meant that already present blood vessel (blood capillary and venule) is by sprouting or splitted mode produces new blood vessel.Under physiology and the pathological conditions, take place as the embryo, processes such as female reproduction cycle, inflammatory reaction, wound healing, tumor generation are all being carried out angiogenesis.Particularly under the pathological conditions, according to statistics, the rise of about 20～40 kinds of human diseasess and angiogenesis or reduce relevant.1971, Folkman has set up the theory of getting in touch between angiogenesis and tumor growth, propose angiogenesis and not only can keep its vigorous metabolism, created advantageous conditions for tumor cell leaves primary lesion by blood transfer again simultaneously for tumor cell provides abundant nutrition.Many tumors are not having can only to grow several millimeters sizes before the new vessels generation, and angiogenesis is suppressed, though tumor cell is carrying out apoptosis fast, so can suppress growth of tumor and transfer effectively simultaneously still breeding at a high speed.Therefore, seek the new vessels growth inhibitor and become in the world neoplasm growth and the another important direction that shifts treatment in recent years.Anti-angiogenic medicaments and other cancer therapy drugs relatively have many advantages, and as seldom producing drug resistance, side effect is little, the efficient height, and the whole world above drugmaker of existing 40 families is developing anti-angiogenic agent.
Since angiogenesis inhibitor treatment in 1988 entered clinical trial, approximately kind of an angiogenesis inhibitor entered clinical trial surplus in the of existing 20, wherein had plenty of at the special molecular such as the interferon-ALPHA that participate in neovascularization; The cell signalling such as the calcium channel blocker of the inhibition calcium mediation that has; Function that then directly suppresses endotheliocyte that has or reaction are as aspergillus fumigatus cedrol (TNP-470).The above-mentioned mechanism of action of analysis-by-synthesis, the better target spot that suppresses angiogenesis is an endotheliocyte, by sealing or reduce its surperficial angiogenic growth factor receptor, suppresses the growth of endotheliocyte, migration and tube chamber form, and can destroy new vessels efficiently and form.And,, act on the receptor of the other vascular endothelial cell of tumor because many malignant tumor cells itself can be secreted angiogenic growth factor for neonate tumour blood vessel, promote tumor vascular growth.So the angiogenesis factor protein expression in the downward modulation tumor cell suppresses the secretion of its angiogenesis factor, also can reach antineoplastic vascular growth effect.
The seventies, Chinese scholar is isolated antimalarial arteannuin (artemisinin) in Chinese herbal medicine Hemerocallis citrina Baroni Artemisia after, Artemether, artesunate (artesunate) and dihydroartemisinine effective derivants such as (dihydroartemisinin) have been synthesized again successively.New milestone is set up in the appearance of this class medicine on the antimalarial agent research history.In up to a million malaria infection were used all over the world, artemisinin-based drug is evident in efficacy, and was little to the human body toxic and side effects, and do not see as yet that so far Drug resistance occurs, and is the important antimalarial of highly effective and safe by world health organisation recommendations.The various countries scholar is to finding that this class medicine also has stronger antitumor action except its special significant malaria curative effect in the research in surplus the artemisinin-based drug ten year.
Arteannuin (Artemisinin) is the sesquiterpene lactones with new structure that China scientist proposed from feverfew Herba Artemisiae annuae (Artemisia annua Linn) first in 1971.It has very good malaria effect, comprises that those have chemical sproof falciparum infection to chloroquine.Cause worldwide attention immediately, owing to exist Orally active low, water-soluble degree is little, and shortcomings such as relapse rate height make to enlarge to use to be restricted.Therefore China scientist has synthesized a large amount of derivants, is dihydroartemisinine (Dihydroartemisinin) according to arteannuin reductive metabolites in vivo, with arteannuin C
10Carbonyl reduction gets dihydroartemisinine, and anti-Mus malaria (P.berghei) is stronger one times than arteannuin.Dihydroartemisinine is carried out esterification get artesunate (Artesunate), chemistry dihydroartemisinine by name-10-α-succinate monoester, its sodium salt is made injectable powder, for quiet notes, the plasmodium phorozoon is had stronger killing action.Artesunate is converted into dihydroartemisinine, i.e. dihydroartemisinine immediately in body.Because dihydroartemisinine is water insoluble, and blood plasma and histone are had stronger adhesion, make medicine rapidly to whole body each tissue transhipment and removing.Therefore, that artesunate has is efficient, quick-acting, low toxicity, be difficult for producing characteristics such as tolerance, all effective to tertian malaria, subtertian malaria, cerebral malaria, the clinical treatment that mainly is applicable to cerebral malaria and various critical malaria.
The dihydroartemisinine artesunate
Summary of the invention
An object of the present invention is to provide a kind of pharmaceutical preparation of blood vessel formation against function, this pharmaceutical preparation mainly contains artesunate or dihydroartemisinine, and its dosage form is mainly injection.
Dosage form provided by the invention is mainly microsphere injection liquid.
Pharmaceutical preparation provided by the invention, be with release polymer mill artesunate or dihydroartemisinine, the melting mixing liquid reuse biocompatibility and the Biodegradable polymer that are prepared into are made injection, and used polymer release posthydrolysis is harmless degradation product.
Second purpose of the present invention provides this pharmaceutical preparation and is applied to that antineoplastic vascular generates and other and associated angiogenesis treatment of diseases, inject injection of the present invention after, can slowly discharge medicine and absorption at medicine-feeding part, prolongation action time.
Pharmaceutical preparation provided by the invention also can have the purposes of chemotherapy of tumors and/or adjuvant chemotherapy aspect.
The present invention has the following advantages:
(1) artesunate and dihydroartemisinine are the most representative medicines in the traditional Herba Artemisiae Annuae class antimalarial, be used for the malaria treatment all the time, characteristics of the present invention are to propose artesunate first and dihydroartemisinine has blood vessel formation against function, and with their medicine as the disease treatment that is used for tumor-blood-vessel growth and other associated angiogenesis.Human numerous disease and associated angiogenesis, artemisinin-based drug will obtain important use as angiogenesis inhibitor in these treatment of diseases.
(2) the present invention provides pharmacodynamics and Its Mechanisms foundation for the artemisinin-based drug exploitation becomes antitumor drug, has the value with artemisinin-based drug exploitation becoming class medicines such as chemotherapy of tumors and/or adjuvant chemotherapy.
(3) microsphere injection liquid dosage form provided by the invention, used polymer release posthydrolysis is harmless degradation product, can slowly discharge medicine and absorption at medicine-feeding part, prolong drug action time.
(4) the present invention is a background with the angiogenesis theory, studies and illustrate effect of Chinese medicine effective monomer component and mechanism, is the new important directions of developing Chinese medicine pharmacology opinion, provides important evidence for finding the new target spot of new theory and drug effect.
Description of drawings
Fig. 1. be the influence of artesunate to the chick chorioallantoic membrane angiogenesis.
Fig. 2 .1a is HE dyeing (Yihong-haematoxylin dyeing).
Fig. 2 .1b is blood vessel CD
31Dyeing.
Fig. 2 .2. is the influence of artesunate to vegf expression.
Fig. 2 .3. is the influence of artesunate to the KDR/flk-1 expression of receptor.
Fig. 3. be transplanted tumor in nude mice change in volume during the medication.
Fig. 4 is the influence to vascular endothelial cell proliferation of artesunate and dihydroartemisinine.
Fig. 5 is the influence to migration of vascular endothelial cells of artesunate and dihydroartemisinine.
Fig. 6 is the influence to the molding of vascular endothelial cell tubule of artesunate and dihydroartemisinine.
Fig. 7 .1 is the influence of dihydroartemisinine to migration of vascular endothelial cells.
Fig. 7 .2 is the influence of dihydroartemisinine to the molding of vascular endothelial cell tubule.
The specific embodiment
The present invention is described further with accompanying drawing in conjunction with specific embodiments.Should be understood that these embodiment only are used for illustration purpose, and be not used in the restriction scope of the invention.
Embodiment 1: a kind of method of preparation artesunate microsphere injection liquid
(Polycaprolactone PCL) grinds artesunate, and the melting mixing liquid that is prepared into is made microsphere injection liquid with biocompatibility and Biodegradable polymer with release polymer.Used polymer release posthydrolysis is harmless degradation product (water and carbon dioxide).After this microsphere injection liquid intramuscular injection, slowly discharge medicine and absorption, prolonged action time, can be used for the disease treatment of tumor and other associated angiogenesis at medicine-feeding part.
Embodiment 2: the whole angiogenesis that suppresses of artesunate microsphere injection liquid is tested
(1) suppresses the chick chorioallantoic membrane angiogenesis
Experiment material: artesunate (crude drug is provided by Guilin second pharmaceutical factory) adopts microsphere injection liquid of the present invention; Hydrocortisone (Xianju, Zhejiang pharmaceutical factory product); Hatching egg (purchasing) in Hangzhou Ilex purpurea Hassk.[I.chinensis Sims name chicken plant.
Method: 7-8 days Embryo Gallus domesticus is windowed, add artesunate, positive reference substance (hydrocortisone) and solvent control product (blank microsphere injection liquid) respectively, behind the hatching 24h, with the fixing chick chorioallantoic membrane of 1: 1 mixed liquor of methanol, acetone, make specimen, counting blood vessel number under anatomic microscope.
The result:
The angiogenesis suppression ratioArtesunate is respectively 50%, 55.6%, 87.5% and 100% to chick chorioallantoic membrane angiogenesis suppression ratio when dosage 15,30,60,80 μ g/ embryos.The suppression ratio 66% of positive controls hydrocortisone 30 μ g/ embryos, the suppression ratio 0% of the blank microsphere injection liquid/embryo of solvent control group isometric(al).Every embryo administration volume 100 μ l.The results are shown in Table 1.
Table 1 artesunate is to the inhibitory action of chick chorioallantoic membrane angiogenesis
Dosage
The tunica vasculose number positiveTunica vasculose tunica vasculose inhibiting rate medicine (μ g/ embryo)+++ the blank microballoon liquid of negative number survival number % 30 00 10 10 0 Artesunates 15 909 18 50.0 Artesunates 30 828 18 55.6 Artesunates 60 3 11 2 16 87.5 Artesunates 80 0 10 0 10 100.0 hydrocortisones 30 354 12 66.7
Vascular countsThe vessel density of solvent control group, branch are obviously more than the administration group, and caliber is thicker, referring to Fig. 1, wherein: (a) solvent control, (b) artesunate 30 μ g/ embryos, (c) hydrocortisone 30 μ g/ embryos.During the high concentration administration, have only the tiny blood vessel of only a few caliber, do not have obvious branch-like, even do not see and haemolysis occurs by blood vessel, indivedual chicken embryo deaths.When artesunate dosage 60,30,15 μ g/ embryos, vascular counts is respectively 3.8,9.7,27.1,19.5 of positive controls, 40.5 of solvent control groups.Compare with the solvent control group, each is organized data and is significant difference (P＜0.01).The results are shown in Table 2.
Table 2 artesunate is counted blood vessel number (blank microsphere liquid 30 15 40.6 ± 2.3 artesunate 15 15 27.1 ± 8.5 of x ± s) to drug dose (the μ g/ embryo) n that influences of chick chorioallantoic membrane angiogenesis
*Artesunate 30 15 9.7 ± 2.7
*Artesunate 60 15 3.8 ± 1.6
*Hydrocortisone 30 15 19.5 ± 5.6
*
*The blank microsphere liquid of P＜0.01vs3%, t test
(2) suppress human ovarian cancer transplanted tumor in nude mice angiogenesis
Experiment material: artesunate (crude drug is provided by Guilin second pharmaceutical factory) adopts microsphere injection liquid of the present invention.HO-8910 human oophoroma cell line (providing) by the institute of oncology, Zhejiang Province, 32 of BALB/C nude mouses, body weight (20 ± 2) g, male, 6～8 ages (providing) in week by the Shanghai Inst. of Tumor.The RPMI-1640 cell culture fluid that contains 10% calf serum.VEGF (VEGF) polyclonal antibody (the anti-people of rabbit, U.S. Santa Cruz company), VEGFR-2 (KDR/flk-1 receptor) polyclonal antibody (the anti-people of rabbit, U.S. Santa Cruz company), CD
31Factor monoclonal antibodies (rat anti-mouse, U.S. Santa Cruz company).
Method:
Suppress human ovarian cancer transplanted tumor in nude mice modelling and dosage regimen Add 10% calf serum with RPMI-1640 and cultivate the HO-8910 Proliferation of Human Ovarian Cell.Cell is by 1 * 10
7/ ml is suspended in the serum-free medium, every mice left side axil subcutaneous vaccination 0.2ml.Can form macroscopic tumor piece, tumor formation rate 100% in about about 4 days.Beginning administration in the 3rd day is divided into 4 groups: artesunate high dose group 100mg/ (kgd), middle dosage group 50mg/ (kgd), low dose group 10mg/ (kgd) and blank microsphere injection liquid group at random after the one-tenth tumor.Every group 8, administered intramuscular, every day 1 time, successive administration 10 days, matched group wait the blank microsphere injection liquid of capacity.After the last administration 24 hours, put to death animal, take out the tumor piece.
The toxic and side effects of gross tumor volume variation and medicineObserve ordinary circumstance and the growth of xenografted situation of nude mouse during the administration, gross tumor volume of per 3 days mensuration.Measuring method is: with vernier caliper measurement tumor major axis (a), minor axis (b) is according to formula V=0.5ab
2Calculate gross tumor volume, draw the gross tumor volume growth curve.Measure the nude mice body weight simultaneously.
HE dyeing and SABCAbove-mentioned tumor tissues specimen is made the thick paraffin section of 5 μ M after routine is handled, HE dyeing, and referring to Fig. 2 .1a, conventional index is observed.With SABC SABC method, adopt mouse-anti Mus CD
31Factor antibody, rabbit anti-people VEGF antibody and rabbit human VEGFR-3 resistant-2 antibody test tumor specimen medium vessels generate, and VEGF and KDR/flk-1 expression of receptor replace an anti-feminine gender of doing with BPS.1. vascular counts: select 6 visuals field to observe blood vessels and counting under every section high power lens (* 200) at random, averaging is the end value of every example.2. VEGF and KDR/flk-1 expression of receptor: select 6 visuals field at random under every section high power lens (* 400), the number of cells of VEGF and KDR/flk-1 receptor positive in 200 cells of counting in each visual field, less than 10% positive cell negative (-), 10%-30% is the weak positive (+), 30%-70% is the middle positive (++), and 70%-100% is strong positive (+++).VEGF expresses in the tumor cell slurry, and the KDR/flk-1 receptor all has expression in tumor cell and vascular endothelial cell, and the expressive site immunohistochemical staining is pale brown color.
The result:
Vascular countsHigh dose group (100mg kg
-1d
-1), middle dosage group (50mg kg
-1d
-1) and low dose group (10mg kg
-1d
-1) blood vessel CD
31Dyeing, the result is referring to Fig. 2 .1b.Vascular counts is respectively 11.61 ± 4.32,27.75 ± 8.04,47.92 ± 11.49, blank microsphere injection liquid group is 48.98 ± 9.40, compare higher, middle dosage group vascular counts with blank microsphere injection liquid matched group and all obviously reduce (P＜0.01), low dose group no significant difference (P＞0.05).Referring to table 3.
Table 3 artesunate influences group (mg/kgd) number of animals (n) vessel density (dosage 50 8 27.75 ± 8.04 in blank microsphere (10ml/kg.d) 8 48.98 ± 9.40 low dosages 10 8 47.92 ± 11.49 of x ± s) to the transplanted tumor in nude mice vessel density
* High dose 100 8 11.61 ± 4.32
*
*P＜0.05,
*The blank microsphere group of P＜0.01 vs, the t check
The VEGF.KDR/flk-1 protein expressionTreatment group and blank microsphere injection liquid group VEGF, the KDR/flk-1 receptor in tumor cell and vascular cell The positive expression rate referring to Fig. 2 .2, Fig. 2 .3, among Fig. 2 .2: (a) dosage group, (c) negative control group in blank microsphere injection liquid group, (b) artesunate, among Fig. 2 .3: (a) dosage group, (c) artesunate high dose group in blank microsphere injection liquid group, (b) artesunate.High dose group (100mg/kgd), middle dosage group (50mg/kgd) and low dose group (10mg/kgd) VEGF, flt-1 immunohistochemical staining positive rate compare with matched group all notable difference (P＜0.05).See Table 4.
Table 4 artesunate to tumor tissues VEGF and
KDR/Flt-1 expresses influences group number of animals vegf expression
KDR/Flk-1 expresses (mg/kgd) (n) blank microsphere 8 of tumor cell tumor cell vascular endothelial cell +++(8) ++ and+(7) ++ (1) ++ and+(8) 10 8 +++(4) ++ (4) +++(3) ++ (5) +++(2) ++ (6)
*50 8 ++ (1)+(4)-(3)
*++ (4)+(3)-(1)
*++ (2)+(4)-(2)
*100 8 ++ (1)+(2)-(5)
*++ (2)+(2)-(4)
*++ (1)+(2)-(5)
*
*P＜0.05,
*The blank microsphere group of P＜0.01vs, x
2Check
The toxic and side effects of gross tumor volume variation and medicineGrowth of xenografted and change in volume are referring to Fig. 3, and when becoming tumor (inoculating after 4 days), treatment group and blank microsphere injection liquid group tumor body difference in size do not have significance (P＞0.05).In the medication process, treatment group tumor growth is slower, and medication the 1st, 4 was measured gross tumor volume in 7,10 days, and height, middle dosage group gross tumor volume have significant difference (P＜0.05) all less than matched group.During the medication, four groups of tumor bearing nude mices are movable good, do not see special untoward reaction, and none example is dead.Medication is matched group and height after 10 days, in, low treatment group on average goes tumor Mus heavy (g) to be respectively 22.1 ± 1.86,22.62 ± 2.4, and 21.83 ± 2.1,22.25 ± 2.36, treatment group and blank microsphere injection liquid matched group relatively do not have significant difference (P＞0.05).
Embodiment 3: artesunate and the experiment of dihydroartemisinine vitro inhibition angiogenesis
Experiment material: artesunate, dihydroartemisinine (crude drug is provided by Guilin second pharmaceutical factory)
Method:
(1) Human umbilical vein endothelial cells (HUVEC) is cultivated
Get the fetal cord of fresh and healthy, pour into 5% collagenase, 37 ℃ of water-bath 15～20min are with PBS liquid flushing umbilical vein, centrifugal, abandon supernatant, use the culture fluid suspension cell, put in the culture bottle and cultivate, change liquid every other day once, culture fluid is that DMEM contains 15% calf serum and the VEGF of 10ng/ml.Use with getting the cell confession research of the 2nd～3 generation after the evaluation of the anti-people VIII of rabbit factor antibody row SABC.
(2) HUVEC propagation suppresses
With HUVEC with 5 * 10
4Individual/ml density is inoculated in 24 well culture plates, puts incubator 5%CO
2, 37 ℃ hatch treated in 24 hours fully adherent after, add medicine (artesunate or dihydroartemisinine), and establish normal saline and DMSO matched group.Establish 3 multiple holes for every group, act on after 48 hours, detect cell survival rate with mtt assay.
(3) the HUVEC migration suppresses
Be grown in the HUVEC that has been fused to monolayer in the 35mm plastic culture dish with the blade damage,, add the DMEM culture fluid that contains 15% calf serum, add testing drug (artesunate or dihydroartemisinine) then, put 5% CO with PBS liquid flushing 3 times
2, in 37 ℃ of incubators, the HUVEC number that from injured edge continuous counter (500 * 250) μ M section, moves after 24 hours, 10 of numeric representations are the cell number average in the visual field at random.
(4) the HUVEC tubule forms and suppresses
Type i collagen (Sigma, Bornem Belgium), DMEM (* 10), 0.05M NaOH+0.2MHEPES+0.26MNaHCO
2With volume ratio 8: 1: 1: mix rapidly down in ice bath, coat 24 well culture plates bottom, put 37 ℃ and form collagen gels, with HUVEC with 5 * 10
4The density of individual/ml is suspended in the 10% calf serum DMEM culture fluid, and every hole adds 0.5ml, and used medicine (artesunate or dihydroartemisinine) also adds with certain concentration at this moment, at 5% CO
2, cultivated 48 hours in 37 ℃ of incubators, (* 200) measure the total length of tubule in 10 visuals field at random with trisquare under inverted microscope.
The result:
(1) influence that HUVEC is bred
Normal saline matched group and DMSO matched group OD value are 0.71 ± 0.05 and 0.72 ± 0.05.Compare with the corresponding solvent matched group, all not obvious to the HUVEC inhibited proliferation when drug level is 0.5 μ mol/L, the OD value of artesunate and dihydroartemisinine is 0.70 ± 0.04 and 0.69 ± 0.07 (P＞0.05); When concentration was 2.5 μ mol/L, the OD value of dihydroartemisinine was 0.66 ± 0.04 (P＜0.05), and the propagation of HUVEC is had inhibitory action; When concentration was 12.5 and 50 μ mol/L, two kinds of medicines all had tangible inhibited proliferation (P＜0.01) to HUVEC, and the OD value is respectively 0.59 ± 0.04,0.42 ± 0.03 (artesunate) and 0.50 ± 0.04,0.36 ± 0.03 (dihydroartemisinine); The OD value descend have dose dependent, each medication group difference have significance (P＜0.05, n=3).Drug level (μ mol/L) is seen ginseng Fig. 4 (n=3), wherein (▲) artesunate, (■) dihydroartemisinine with the relation of cell survival rate (%).
(2) influence that HUVEC is moved
The cell migration experimental result shows, under the effect of artesunate and dihydroartemisinine, the quantity that the HUVEC migration enters injured exposed area obviously reduces, referring to Fig. 5, Fig. 7 .1, among Fig. 5: (▲) artesunate, (■) dihydroartemisinine, among Fig. 7 .1: (a) solvent control, (b) 2.5 μ M dihydroartemisinines, (c) 50 μ M dihydroartemisinines.
The cell number of normal saline and DMSO matched group HUVEC migration is 256 ± 28 and 258 ± 29.When drug level was 0.5 μ mol/L, the migration inhibitory action was not obvious, and artesunate and dihydroartemisinine group cell migration number are 252 ± 46 and 241 ± 23 (P＞0.05); When concentration is 2.5,12.5,50 μ mol/L, significant difference (P＜0.01) is arranged between medication group and the matched group, artesunate and dihydroartemisinine group migrating cell number are respectively 182.6 ± 25,88.7 ± 11,7.6 ± 6 and 147 ± 18,45 ± 9,1.5 ± 1.The relation of drug level (μ mol/L) and cell migration rate (%) is referring to Fig. 5 (n=3).
(3) artesunate and dihydroartemisinine are to the influence of HUVEC tubule molding
HUVEC grew in collagen gel substrate 2～3 days the time, and cell becomes spindle shape by original polygon, and in gel-type vehicle elongation growth, be linear array and form tubular structure, a plurality of tubular structures are interconnected to form tridimensional network.Referring to Fig. 6, Fig. 7 .2, among Fig. 6: (▲) artesunate, (■) dihydroartemisinine, among Fig. 7 .2: (a) solvent control, (b) 12.5 μ M dihydroartemisinines, (c) 50 μ M dihydroartemisinines.
Behind the 48h, the tubule total length is 4.90 ± 0.55mm and 5.18 ± 0.65mm in normal saline and each visual field of DMSO matched group; When drug level was 0.5 μ mol/L, little length of tube of medication group and matched group did not more all have significant difference (P＞0.05); When drug level was 2.5 μ mol/L, dihydroartemisinine group tubule total length was 3.85 ± 0.35mm, presented obvious suppression effect (P＜0.05); When concentration was 12.5,50 μ mol/L, two kinds of medicines all had significant tubule inhibitory action (P＜0.01).Artesunate and dihydroartemisinine group tubule total length are respectively 3.47 ± 0.32mm, 1.30 ± 0.08mm and 1.65 ± 0.73mm, 0.42 ± 0.02mm.Relation between drug level (μ mol/L) and the tubule formation rate (%) is referring to Fig. 6 (n=3).The partial reference document that the present invention relates to: [1] Folkman J.Angiogenesis in cancer, rheumatoid and disease.Nat Med 1995,1:27-31.[2] Kim KJ, Li B, Winer J.Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo.Nature 1993,362:841-844.[3] Klayman DL.Qinghaosu (artemisinin): an antimalarial drug from China.Science 1985,228:1049-1055.[4] Benakis A, Paris M, Loutan L, et al.Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers.Am J Trop Med Hyg 1997,56:17-23.[5] Efferth T, Dunstan H, Sauerbrey A, et al.The anti-malarial artesunate is also active against cancer.Int J Oncol 2001,18:767-773.[6] Moore JC, Lai H, Li JR, et al.Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat.Cancer Lett 1995,98:83-87.[7] Jaffe EA, Nachman RL, Becker CG, et al.Culture of human endothelial cells derived from umbilical veins.Identification by morphologic and immunologic criteria.J Clin Invest 1973,52:2745-2756.[8] Satake S, Kuzuya M, Ramas MA, et al.Angiogenic stimuli are essential for survival of vascular endothelial cells in three-dimensional collagen lattice. Biochem Biophys Res Commun 1998,244:642-646.[9] Weidner N, Sample JP, Folkman J, et al.tumor angiogenesis and metastasis-correlation in invasive breast carcinoma.N Engl J Med 1991,324,1-8.[10] Klagsbrun M, Moses MA.Molecular angiogenesis.Chem Biol 1999,6:217-224.[11] Ferrara N, Houck I, Jakeman L, et al.Molecular and biological properties of the
vascular?endothelial?growth?factor?family?of?proteins.Endocr?Rev?1999，
13：18-42.[12]Shen?BO，Lee?DR，Zioncheck?TF?Vascular?endothelial?growth?factor?governs
endothelial?nitric-oxide?synthase?expression?via?KDR/Flk-1?receptor?and?a
protein?kinasa?C?signaling?pathway.J?boil?Chem?1999，274：33057-33063.[13]Claffey?KP，Brow?LF，Aguila?LF?Expression?of?vascular?permeability?factor/
vascular?endothelial?growth?factor?by?melanoma?cells?increases?tumor?growth，
angiogenesis，and?experimental?metastasis.Cancer?Res?1996，56：172-182.
All documents that the present invention mentions are all quoted in application as a reference, are just all quoted as a reference separately as each piece document.Should understand in addition, the present invention is described in conjunction with most preferred embodiment, yet after having read foregoing of the present invention, those skilled in the art can make various changes or modifications the present invention, and these equivalent form of values fall within the application's appended claims institute restricted portion equally.
Claims (5)
1. the pharmaceutical preparation and the purposes of artesunate and dihydroartemisinine blood vessel formation against function, it is characterized in that: this pharmaceutical preparation mainly contains artesunate or dihydroartemisinine, and its dosage form is mainly injection.
2. the pharmaceutical preparation of blood vessel formation against function as claimed in claim 1, it is characterized in that: dosage form is mainly microsphere injection liquid.
3. as the pharmaceutical preparation of claim 1 and 2 described blood vessel formation against function, it is characterized in that: with release polymer mill artesunate and dihydroartemisinine, reuse biocompatibility and Biodegradable polymer are made microsphere injection liquid.
4. as the pharmaceutical preparation and the purposes of claim 1 and 2 described blood vessel formation against function, it is characterized in that: said preparation has antineoplastic vascular to generate and the purposes of other and associated angiogenesis disease treatment.
5. as the pharmaceutical preparation and the purposes of claim 1 and 2 described blood vessel formation against function, it is characterized in that: said preparation also is useful on the purposes of chemotherapy of tumors and/or adjuvant chemotherapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03116762 CN1208061C (en) | 2003-04-29 | 2003-04-29 | Artesunate and dihydroarteannuin medicine preparation for proofing formation of blood vessel and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03116762 CN1208061C (en) | 2003-04-29 | 2003-04-29 | Artesunate and dihydroarteannuin medicine preparation for proofing formation of blood vessel and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1448138A true CN1448138A (en) | 2003-10-15 |
| CN1208061C CN1208061C (en) | 2005-06-29 |
Family
ID=28684256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03116762 Expired - Fee Related CN1208061C (en) | 2003-04-29 | 2003-04-29 | Artesunate and dihydroarteannuin medicine preparation for proofing formation of blood vessel and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1208061C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1295231C (en) * | 2005-01-12 | 2007-01-17 | 四川科伦药业股份有限公司 | Bromo-dihydroartemisine |
| CN1312157C (en) * | 2005-01-12 | 2007-04-25 | 四川科伦药业股份有限公司 | Halogenated dihydroartemisine, preparation and use thereof |
| CN1833644B (en) * | 2005-03-18 | 2010-07-21 | 中国人民解放军第三军医大学 | Abrotine, its derivative dihydro-abrotine, artemether, arteether and arte sunate in use of pharmacy |
| CN107569482A (en) * | 2017-08-29 | 2018-01-12 | 昆药集团股份有限公司 | Artemisine compounds are preparing the application in treating embryonal-cell lipoma medicine |
| CN109602739A (en) * | 2019-01-18 | 2019-04-12 | 苏州大学 | Artesunate inhibits the application in tumor cell drug resistance drug in preparation |
| CN109874293A (en) * | 2016-08-02 | 2019-06-11 | 斑马药研公司 | Reduce the small molecule therapy compound of the disease incidence of intracerebral hemorrhage and Cerebral microbleeds |
| CN110448551A (en) * | 2019-08-23 | 2019-11-15 | 西南大学 | Dihydroqinghaosu is preparing the application in anti-angiogenic medicaments |
-
2003
- 2003-04-29 CN CN 03116762 patent/CN1208061C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1295231C (en) * | 2005-01-12 | 2007-01-17 | 四川科伦药业股份有限公司 | Bromo-dihydroartemisine |
| CN1312157C (en) * | 2005-01-12 | 2007-04-25 | 四川科伦药业股份有限公司 | Halogenated dihydroartemisine, preparation and use thereof |
| CN1833644B (en) * | 2005-03-18 | 2010-07-21 | 中国人民解放军第三军医大学 | Abrotine, its derivative dihydro-abrotine, artemether, arteether and arte sunate in use of pharmacy |
| CN109874293A (en) * | 2016-08-02 | 2019-06-11 | 斑马药研公司 | Reduce the small molecule therapy compound of the disease incidence of intracerebral hemorrhage and Cerebral microbleeds |
| CN107569482A (en) * | 2017-08-29 | 2018-01-12 | 昆药集团股份有限公司 | Artemisine compounds are preparing the application in treating embryonal-cell lipoma medicine |
| CN109602739A (en) * | 2019-01-18 | 2019-04-12 | 苏州大学 | Artesunate inhibits the application in tumor cell drug resistance drug in preparation |
| CN110448551A (en) * | 2019-08-23 | 2019-11-15 | 西南大学 | Dihydroqinghaosu is preparing the application in anti-angiogenic medicaments |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1208061C (en) | 2005-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1058717A (en) | New antimalarial agent-Coartem and preparation method thereof | |
| KR100861428B1 (en) | Fatty acid analogues for the treatment of cancer | |
| CN113304123A (en) | Bionic nano-drug loaded with JTC801 and DNA (deoxyribonucleic acid) methylation transferase inhibitor together, preparation method and application | |
| CN102526022A (en) | Application of epigallocatechin-3-gallate in preparation of antitumor drug | |
| CN1208061C (en) | Artesunate and dihydroarteannuin medicine preparation for proofing formation of blood vessel and use thereof | |
| CN101647796A (en) | Application of osthole in preparing anti-angiogenic drugs | |
| CN1287127A (en) | Folica acid-polysaccharide composite and its preparation and medical composition with the composite as active component | |
| CN102920729B (en) | Application of oligomerization mannuronic acid and medicinal salts of oligomerization mannuronic acid in preparing medicine for leucopenia prevention | |
| CN101411746A (en) | Novel use of salvia root extract | |
| CN103251585B (en) | Arteannuin and derivant thereof are in the effect suppressed in platelet derived growth factor receptor A and application thereof | |
| CN102198125B (en) | Purpose of phenethyl caffeate derivatives in preparation of medicines for inhibiting angiogenesis of tumors | |
| CN101125140B (en) | Application of dihydroartemisinin in reinforcing chemotherapy medicine antitumor curative effect | |
| CN1846694A (en) | Substituted aromatic radical biguanide compounds and the application of their medicine composition in preparing medicine for resisting malignant tumors | |
| CN101264069A (en) | Application of resveratrol derivative in preparing medicine for treating disease relative to immune | |
| RU2549441C2 (en) | Methods and pharmaceutical compositions for treating down syndrome | |
| CN109602752A (en) | Triptolide is in induction cancer cell autophagy and hdac inhibitor is cooperateed with to treat the application in tumour | |
| CN108096239B (en) | A pharmaceutical composition for treating brain glioma and hepatocarcinoma | |
| CN108451905B (en) | Gambogic acid nanoemulsion preparation and preparation method and application thereof | |
| CN103127061A (en) | Medicine application of chloranthus japonicus alcohol M | |
| CN101224200B (en) | Novel anti-systematic erythema lupus medicine | |
| CN111249274A (en) | Application of ginkgolide B in preparation of glioma cell activity inhibitor | |
| CN109481688A (en) | Pharmaceutical composition containing chemotherapeutics and Berbamine hydrochloride | |
| CN107693509A (en) | SB FI 26 are preparing the application in treating breast cancer medicines | |
| CN103127062A (en) | Application of 13'-acetyl silver grass alcohol C in manufacturing of antineoplastic drugs | |
| CN101664401A (en) | Application of usnic acid in preparation of drugs inhibiting angiogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050629 Termination date: 20150429 |
|
| EXPY | Termination of patent right or utility model |